The TVM Capital Life Science Venture Practice in Montréal reinforces its
investment team with Dr. Marc Rivière, MD, who will start his tenure as a General Partner in August.
MONTREAL, July 8, 2013 /CNW Telbec/ - Marc Rivière will join the
Montréal-based Managing Partners, Dr. Hubert Birner and Dr. Luc
Marengère as well as General Partner Dr. Cynthia Lavoie. Marc Rivière
has been a Québec resident for close to 20 years. He brings a broad
product development experience backed by many years in leadership roles
with service providers and with entrepreneurially led companies such as
Axcan Pharma. At TVM Life Science Management Inc., he will focus on
evaluation of deal opportunities and investment management for
therapeutics. He will also work closely with the firm's strategic
partner Eli Lilly & Co. and its drug development division Chorus.
Dr. Luc Marengère, Managing Partner of TVM Life Science Management Inc.
says: "Marc will be an outstanding addition to our investment team. His
experience, network and understanding of how early stage life-science
projects are to be managed, will be an invaluable addition to our
practice. We all look forward to start working with Marc."
Montréal's TVM Life Science Management Inc., an advisor to TVM Life Science
Ventures VII, follows a capital efficient investment approach to
developing individual pharmaceutical assets to a human proof-of-concept
About the Life Science Investment Group of TVM Capital
TVM Capital Life Science is providing venture capital to the
international pharmaceutical, biopharmaceutical and medical technology
industries with more than 25-years of transatlantic investment track
record and in excess of US$1.1bn under management. The Life Science
Investment Group's mission is to invest in the development of exciting
early stage drug candidates and companies in the medical field that are
or aspire to be innovative leaders in their market segment. Since 1984,
TVM Capital Life Science made 117 investments in life science companies
in Europe and the United States and exited from 87 companies, including
42 initial public offerings on the NASDAQ, and the London, Frankfurt,
Zurich and Vienna Stock Exchanges and 25 trade sales and mergers. The
Life Science team combines long-standing international investment and
company building experience with their track record of dedicated board
work, extensive global networks in the world of life science research
and product development and a direct knowledge of the local markets.
TVM Capital Life Science currently invests from its 7th fund
generation, TVM Life Science Ventures VII, with an integrated team of
investment professionals based in in Montréal and Munich.
More information: www.tvm-lifescience.com or twitter: tvmcapital
SOURCE: TVM Capital
For further information:
TVM Life Science Management Inc.
2 Place Alexis Nihon, Suite 902
3500 Blvd De Maisonneuve West, Westmount,
Montréal, QC H3Z 1X5 Canada
+1 514 931 4111